Publications by authors named "Annieke C G van Baar"
Article Synopsis
- * The study included 14 patients on insulin, where ReCET was performed with optimized electroporation doses, and patients were switched to a glucagon-like peptide 1 receptor agonist afterwards.
- * Results indicated that ReCET was safe and effective, with 86% of patients remaining off insulin after 12 months and showing significant improvements in their blood sugar levels.
Article Synopsis
- The metabolic syndrome (MetSyn) is a major global health challenge, consisting of various metabolic disorders like obesity, high blood pressure, and high blood sugar, which increase cardiovascular risk.
- Recent research highlights the significance of the gut microbiome in understanding these disorders, revealing how gut microorganisms affect metabolic processes and overall health.
- This review examines the relationship between the gut microbiome and MetSyn, exploring how this connection could lead to new treatment options for metabolic disorders and obesity.
Background And Aims: The duodenum has been shown to play a key role in glucose homeostasis. Duodenal mucosal resurfacing (DMR) is an endoscopic procedure for patients with type 2 diabetes (T2D) in which the duodenal mucosa is hydrothermally ablated. DMR improves glycemic control, but the underlying mechanisms remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- The gut microbiota plays a crucial role in how our bodies metabolize nutrients and manage digestion, with new procedures like Duodenal Mucosal Resurfacing (DMR) showing promise in improving metabolic health for patients with type 2 diabetes.
- In a study, 69% of insulin-dependent type 2 diabetes patients discontinued insulin treatment after undergoing DMR combined with a glucagon-like peptide-1 receptor agonist, leading to better blood sugar control.
- Analysis of gut microbiota showed correlations between changes in diversity and metabolic health outcomes, but no significant diversity changes were found within three months, indicating that further research is needed to understand these relationships better.
Aims: Duodenal mucosal resurfacing (DMR) is an endoscopic procedure developed to improve metabolic parameters and restore insulin sensitivity in patients with diabetes. Here we report long-term DMR safety and efficacy from the REVITA-1 study.
Materials And Methods: REVITA-1 was a prospective, single-arm, open-label, multicenter study of DMR feasibility, safety, and efficacy in patients with type 2 diabetes (hemoglobin A1c [HbA1c] of 7.
Duodenal mucosal resurfacing (DMR) is a new endoscopic ablation technique aimed at improving glycemia and metabolic control in patients with type 2 diabetes mellitus (T2DM). DMR appears to improve insulin resistance, which is the root cause of T2DM, but its mechanism of action is largely unknown. Bile acids function as intestinal signaling molecules in glucose and energy metabolism via the activation of farnesoid X receptor and secondary signaling [e.
View Article and Find Full Text PDFBackground And Aims: Duodenal mucosal resurfacing (DMR) is an endoscopic intervention in which the duodenal mucosa is ablated by hydrothermal energy. DMR improves glycemic control in patients with type 2 diabetes (T2D), most likely by altered duodenal signaling leading to insulin sensitization. We studied whether we could discontinue insulin use in T2D patients by combining DMR with glucagon-like peptide-1 receptor agonist (GLP-1RA) and lifestyle counseling.
View Article and Find Full Text PDFDuodenal mucosal resurfacing (DMR) is an endoscopic procedure which improves insulin resistant metabolic disease, including type 2 diabetes mellitus (T2DM). The aim of this report was to evaluate the feasibility and procedural aspects of DMR and to provide more specific DMR procedural guidance for endoscopists. In this international multicenter, prospective, open-label study, patients on oral anti-diabetic agents for treating T2DM underwent single DMR.
View Article and Find Full Text PDFUnlabelled: Insulin resistance is a core pathophysiological defect underscoring type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Both conditions improve with duodenal exclusion surgery. Duodenal mucosal resurfacing (DMR) is an endoscopic intervention developed to treat metabolic disease which has been shown to improve glycaemia in patients with poorly controlled T2DM.
View Article and Find Full Text PDFBackground: The duodenum has become a metabolic treatment target through bariatric surgery learnings and the specific observation that bypassing, excluding or altering duodenal nutrient exposure elicits favourable metabolic changes. Duodenal mucosal resurfacing (DMR) is a novel endoscopic procedure that has been shown to improve glycaemic control in people with type 2 diabetes mellitus (T2D) irrespective of body mass index (BMI) changes. DMR involves catheter-based circumferential mucosal lifting followed by hydrothermal ablation of duodenal mucosa.
View Article and Find Full Text PDFBackground: Enteroendocrine cells are essential for the regulation of glucose metabolism, but it is unknown whether they are associated with clinical features of metabolic syndrome (MetS) and fasting plasma metabolites.
Objective: We aimed to identify fasting plasma metabolites that associate with duodenal L cell, K cell and delta cell densities in subjects with MetS with ranging levels of insulin resistance.
Research Design And Methods: In this cross-sectional study, we evaluated L, K and delta cell density in duodenal biopsies from treatment-naïve males with MetS using machine-learning methodology.